Literature DB >> 22749533

Interferon-γ, tumor necrosis factor, and interleukin-18 cooperate to control growth of Mycobacterium tuberculosis in human macrophages.

Cory M Robinson1, Joo-Yong Jung, Gerard J Nau.   

Abstract

Mycobacterium tuberculosis (MTB) remains a leading infectious threat to human health. Macrophages are the cells targeted for infection by the bacterium as well as key effector cells for clearance of the pathogen. Interleukin (IL)-27 opposes macrophage-mediated control of MTB because supplying IL-12 and blocking the activity of IL-27 limits bacterial growth in primary human macrophages. The purpose of this study was to determine the immunological regulators of this macrophage mechanism to restrict MTB growth. Interferon (IFN)-γ, TNF-α, and IL-18 were all demonstrated to be important to the environment that limits bacterial growth when IL-12 is supplied and IL-27 is neutralized. We find IL-18 works in conjunction with IL-12 to achieve optimal IFN-γ production in this system. We also demonstrate novel interactions between these cytokines to influence the expression or responsiveness to one another. Quantitative assays show that IFN-γ enhances expression of the IL-18 receptor signaling chain, as well as TNF expression and secretion. In turn, TNF-α augments expression of the receptor for IFN-γ, the amount at the cell surface, and the extent of IFN-γ -induced signaling. We further define how the cytokine environment supports an enhanced state of classical macrophage activation. Collectively, these results describe novel immunological mechanisms that provide additional insights into the effects of IL-12 and IL-27 on macrophage regulation during MTB infection.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749533      PMCID: PMC3429699          DOI: 10.1016/j.cyto.2012.06.012

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  29 in total

1.  IFN-alpha and IL-18 exert opposite regulatory effects on the IL-12 receptor expression and IL-12-induced IFN-gamma production in mouse macrophages: novel pathways in the regulation of the inflammatory response of macrophages.

Authors:  L Fantuzzi; P Puddu; B Varano; M Del Cornò; F Belardelli; S Gessani
Journal:  J Leukoc Biol       Date:  2000-11       Impact factor: 4.962

2.  Mycobacterium tuberculosis induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization.

Authors:  Somia Perdow Hickman; John Chan; Padmini Salgame
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

3.  Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.

Authors:  George D Kalliolias; Rachael A Gordon; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

4.  Human macrophage activation programs induced by bacterial pathogens.

Authors:  Gerard J Nau; Joan F L Richmond; Ann Schlesinger; Ezra G Jennings; Eric S Lander; Richard A Young
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

5.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR.

Authors:  Q Chen; N Ghilardi; H Wang; T Baker; M H Xie; A Gurney; I S Grewal; F J de Sauvage
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

6.  WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection.

Authors:  H Yoshida; S Hamano; G Senaldi; T Covey; R Faggioni; S Mu; M Xia; A C Wakeham; H Nishina; J Potter; C J Saris; T W Mak
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

7.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

8.  The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection.

Authors:  Alejandro Villarino; Linda Hibbert; Linda Lieberman; Emma Wilson; Tak Mak; Hiroki Yoshida; Robert A Kastelein; Christiaan Saris; Christopher A Hunter
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

9.  Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2.

Authors:  C A Scanga; V P Mohan; K Yu; H Joseph; K Tanaka; J Chan; J L Flynn
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

10.  The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice.

Authors:  T Mogues; M E Goodrich; L Ryan; R LaCourse; R J North
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  22 in total

1.  Murine myeloid-derived suppressor cells are a source of elevated levels of interleukin-27 in early life and compromise control of bacterial infection.

Authors:  Madeline Gleave Parson; Juanita Grimmett; Jordan K Vance; Michelle R Witt; Brittany G Seman; Travis W Rawson; Logan Lyda; Christopher Labuda; Joo-Yong Jung; Shelby D Bradford; Cory M Robinson
Journal:  Immunol Cell Biol       Date:  2019-02-08       Impact factor: 5.126

2.  The presence of interleukin-27 during monocyte-derived dendritic cell differentiation promotes improved antigen processing and stimulation of T cells.

Authors:  Joo-Yong Jung; Lawton L Roberts; Cory M Robinson
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

3.  Elevated interleukin-27 levels in human neonatal macrophages regulate indoleamine dioxygenase in a STAT-1 and STAT-3-dependent manner.

Authors:  Joo-Yong Jung; Madeline Gleave Parson; Jennifer D Kraft; Logan Lyda; Brianna Kobe; Celestia Davis; Jembber Robinson; Maria Marjorette O Peña; Cory M Robinson
Journal:  Immunology       Date:  2016-09       Impact factor: 7.397

Review 4.  The Goldilocks model of immune symbiosis with Mycobacteria and Candida colonizers.

Authors:  Richard T Robinson; Anna R Huppler
Journal:  Cytokine       Date:  2017-05-29       Impact factor: 3.861

5.  The intracellular environment of human macrophages that produce nitric oxide promotes growth of mycobacteria.

Authors:  Joo-Yong Jung; Ranjna Madan-Lala; Maria Georgieva; Jyothi Rengarajan; Charles D Sohaskey; Franz-Christoph Bange; Cory M Robinson
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

Review 6.  Macrophages in tuberculosis: friend or foe.

Authors:  Evelyn Guirado; Larry S Schlesinger; Gilla Kaplan
Journal:  Semin Immunopathol       Date:  2013-07-18       Impact factor: 9.623

7.  Neonatal macrophages express elevated levels of interleukin-27 that oppose immune responses.

Authors:  Jennifer D Kraft; Joseph Horzempa; Celestia Davis; Joo-Yong Jung; Maria Marjorette O Peña; Cory M Robinson
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 8.  Interleukin-27 and Its Diverse Effects on Bacterial Infections.

Authors:  Yugo Morita; Elysia A Masters; Edward M Schwarz; Gowrishankar Muthukrishnan
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

9.  Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis.

Authors:  Yone Vila Nova Cavalcanti; Maria Carolina Accioly Brelaz; Juliana Kelle de Andrade Lemoine Neves; José Candido Ferraz; Valéria Rêgo Alves Pereira
Journal:  Pulm Med       Date:  2012-11-28

10.  Ficolin-2 defends against virulent Mycobacteria tuberculosis infection in vivo, and its insufficiency is associated with infection in humans.

Authors:  Fengling Luo; Xiaoming Sun; Yubin Wang; Qilong Wang; Yanhong Wu; Qin Pan; Chao Fang; Xiao-Lian Zhang
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.